Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
J. Danesh, R. Newton, V. Beral.
A human germ project?.
Nature, 389 (1997), pp. 21-24
[2.]
J. Danesh, R. Collins, R. Peto.
Chronic infections and coronary heart disease: is there a link?.
Lancet, 350 (1997), pp. 430-436
[3.]
E.A. Gill, T.M. McIntyre, S.M. Prescott, G.A. Zimmerman.
Mechanisms of vascular injury in the pathogenesis of infectious diseases.
Curr Opin Infect Dis, 5 (1992), pp. 381-388
[4.]
P. Vallance, J. Collier, K. Bhagat.
Infection, inflammation and infarction: does acute endothelial dysfunction provide a link?.
Lancet, 349 (1997), pp. 1391-1392
[5.]
S.A. Miller, C.H. Selzman, B.D. Shames, H.A. Barton, S.M. Johnson, A.H. Harken.
Chlamydia pneumoniae activates Nuclear Factor kappaB and Activator Protein 1 in human vascular smooth muscle and induces cellular proliferation.
J Surg Res, 90 (2000), pp. 76-81
[6.]
S.E. Epstein, E. Speir, Y.F. Zhon, E. Guetta, M. Leon, T. Finkel.
The role of infection in restenosis and atherosclerosis: focus on cytomegalovirus.
Lancet, 348(Suppl I (1996), pp. 13-17
[7.]
M.V. Kalayoglu, B. Hoerneman, D. La Verda, S.G. Morrison, R.P. Morrison, G.I. Byrne.
Cellular oxidation of low-density lipoprotein by Chlamydia pneumoniae.
J Infect Dis, 180 (1999), pp. 780-790
[8.]
P. Patel, M.A. Mendall, D. Carrington.
Association of Helicobacterpylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factores.
Bmj, 311 (1995), pp. 711-714
[9.]
M.A. Mendall, P. Patel, L. Ballam, D. Strachan, T.C. Northfield.
C-reactive protein and its relation to cardiovascular risk factores: a population based cross sectional study.
Bmj, 312 (1996), pp. 1061-1065
[10.]
P.M. Ridker, M. Cushman, M.J. Stampfer, R.P. Tracy, C.H. Hennekens.
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
N Engl Med, 336 (1997), pp. 973-979
[11.]
M. Leinonen.
Pathogenetic mechanism and epidemiology of Chlamydia pneumoniae.
Eur Heart J, 14 (1993), pp. 57-61
[12.]
D. Birnie, I.C. McKay, S. Hood, K.E.J. McColl, W.S. Hillis.
Association between antibodies to mycobacterial heat shock protein 65 and coronary atherosclerosis: possible mechanism of action of Helicobacter pylori in increasing cardiovascular risk.
Heart, 75 (1996), pp. 64
[13.]
H. Hu, G.N. Pierce, G. Zhong.
The atherogenic effects of Chlamydia are dependent on serum cholesterol and specific to Chlamydia penumoniae.
J Clin Invest, 103 (1999), pp. 747-753
[14.]
S. Niemela, T. Karttunen, T. Korhonen.
Could Helicobacter pylori infection increase the risk of coronary heart disease by modifying serum lipid concentrations?.
Heart, 75 (1996), pp. 573-575
[15.]
R.K.R. Scragg, A. Fraser, P.A. Metcalf.
Helicobacter pylori seropositivity and cardiovascular risk factors in a multicultural workforce.
J Epidemiol Commun Health, 50 (1996), pp. 578-579
[16.]
J.J.Y. Sung, J.E. Sanderson.
Hyperhomocysteinaemia, Helicobacter pylori, and coronary heart disease.
Heart, 76 (1996), pp. 305-307
[17.]
M.S. Nieminen, K. Mattila, V. Valtonen.
Infection and inflammation as risk factors for myocardial infarction.
Eur Heart J, 14 (1993), pp. 12-16
[18.]
M.L. Wimmer, R. Sandmann-Strupp, P. Saikku.
Association of Chlamydial infection with cerebrovascular disease.
Stroke, 27 (1996), pp. 2207-2210
[19.]
G.H. Dahlen, J. Boman, L.S. Birgander.
Lp(a) lipoprotein, IgG, IgA and IgM antibodies to Chlamydia penumoniae and HLA class II genotype in early coronary artery disease.
Atherosclerosis, 114 (1995), pp. 165-174
[20.]
T. Huittnrn, M. Leinonen, L. Tenkanen, M. Manttari, H. Virkkunen, T. Pitkanen, et al.
Autoimmunity to human heat shock protein 60, Chlamydia pneumoniae infection, and inflammation in predicting coronary risk.
Arterioscl Thromb Vasc Biol, 22 (2002), pp. 431-437
[21.]
K. Bachmaier, N. Neu, L.M. de la Maza.
Chlamydia infections and heart disease linked through antigenic mimicry.
Science, 283 (1999), pp. 1335-1338
[22.]
M. Puolakkainen, C.C. Kuo, A. Shor.
Serological response to Chlamydia penumoniae in adults with coronary arterial fatty streaks and fibrolipid plaques.
J Clin Microbiol, 31 (1993), pp. 2212-2214
[23.]
J.T. Grayston, C.C. Kuo, A.S. Coulson.
Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery.
Circulation, 92 (1995), pp. 3397-3400
[24.]
J.A. Ramirez.
Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. The Chlamydia pneumoniae/Atherosclerosis Study Group.
Ann Intern Med, 125 (1996), pp. 979-982
[25.]
E. Gurfinkel, G. Bozovich, A. Daroca, E. Beck, B. Mautner.
Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study.
Lancet, 350 (1997), pp. 404-407
[26.]
J.L. Anderson, J.B. Muhlestein, J. Carlquist, A. Allen, S. Trehan, C. Nelson, et al.
Randomized secondary prevention trial of azithromycin patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. The azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) Study.
Circulation, 99 (1999), pp. 1540-1547
[27.]
J. Gieffers, H. Füllgraf, J. Jahn, M. Klinger, K. Dalhoff, H.A. Katus, et al.
Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment.
Circulation, 103 (2001), pp. 351-356
[28.]
A. Kutlin, P.M. Roblin, M.R. Hammerschlag.
Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection model antimicrobial agents and chemotherapy.
Antimicrob Agents Chemother, 46 (2002), pp. 409-412
[29.]
C. Zellner, T.M. Chou, V. Pasceri, A. Maseri, G. Cammarota, G. Patti, et al.
Antibiotic prophylaxis and treatment of cardiovascular disease response.
Circulation, 99 (1999), pp. 1922-1926
[30.]
G.Y. Lip, D.G. Beevers.
Can we treat coronary disease with antibiotics?.
Lancet, 350 (1997), pp. 378-379
[31.]
H. Kothe, K. Dalhoff, J. Rupp, A. Muller, J. Kreuzer, M. Maass, et al.
Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae.
Circulation, 101 (2000), pp. 1760-1763
[32.]
S. Gupta, A.J. Camm.
Chlamydia pneumoniae and coronary heart disease: coincidence, association, or causation? BMJ 1997;314:1778-9.
Bmj, 314 (1997), pp. 1778-1779
[33.]
P. Saikku, M. Leinonen, K. Mattila, M.R. Ekman, M.S. Nieminen, P.H. Makela, et al.
Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction.
Lancet, 2 (1988), pp. 983-985
[34.]
P.J. Cook, D. Honeybourne, C.Y.H. Lip, D.G. Beevers, R. Wise.
Chlamydia pneumoniae and acute arterial thrombotic disease.
Circulation, 92 (1995), pp. 3148-3149
[35.]
P. Saikku, M. Leinonen, L. Tenkanen.
Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study.
Ann Intern Med, 116 (1992), pp. 273-278
[36.]
H. Miettinen, S. Lehto, P. Saikku.
Association of Chlamydia pneumoniaeacute coronary heart disease events in non-insulin-dependent diabetic and non-diabetic subjects in Finland.
Eur Heart J, 17 (1996), pp. 682-688
[37.]
P.M. Ridker, R.B. Kundstein, M.J. Stampfer, S. Poulin, C.H. Hennekens.
Prospective study of Chlamydia pneumoniae IgG seropositivity and 0risks of future myocardial infarction.
Circulation, 99 (1999), pp. 1161-1164
[38.]
F.J. Nieto.
Infections and atherosclerosis: new clues from an old hypothesis?.
Am J Epidemiol, 148 (1998), pp. 937-948
[39.]
F. Romeo, E. Martuscelli, G. Chirieolo, L.M. Cerabino, K. Ericson, T.G. Saldeen, et al.
Seropositivity against Chlamydia pneumoniae in patients with coronary atherosclerosis.
Clin Cardiol, 23 (2000), pp. 327-330
[40.]
B. Fagerberg, J. Gnarpe, H. Gnarpe, S. Agewall, J. Wikstrand.
Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease. A prospective study in middle-aged to elderly men with treated hypertension.
Stroke, 30 (1999), pp. 299-305
[41.]
D.P. Strachan, D. Carrington, M.A. Mendall, L. Ballam, J. Morris, B.K. Butland, et al.
Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in the Caerphilly prospective heart disease study.
Bmj, 318 (1999), pp. 1035-1039
[42.]
J.B. Muhlestein.
Antibiotic therapy for treatment of Chlamydia to prevent coronary heart disease events.
Current Atherosclerosis Reports, 2 (2000), pp. 336-341
[43.]
F.J. Nieto, A.R. Folsom, P.D. Sorlie, J.T. Grayston, S.P. Wang.
Chambless LlE, for the Atherosclerosis Risk in Communities (ARIC) Study Investigators. Chlamydia pneumoniae infection and incident coronary heart disease. The Atherosclerosis Risk in Communities Study.
Am J Epidemiol, 150 (1999), pp. 149-156
[44.]
J.T. Grayston.
Antibiotic treatment of Chlamydia pneumoniae for secondary prevention of cardiovascular events.
Circulation, 97 (1998), pp. 1669-16670
[45.]
A.R. Folsom.
Antibiotics for prevention of myocardial infarction? Not yet!.
Jama, 281 (1999), pp. 461-462
[46.]
E. Gurfinkel, G. Bozovich, E. Beck, E. Testa, B. Livellara, B. Mautner.
for the ROXIS Study Group. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS study.
Eur Heart J, 20 (1999), pp. 121-127
Copyright © 2003. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.